The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer
Xiaoli Wei, Qi‐Nian Wu, Dongliang Chen, Zhao-Lei Zeng, Jiabin Lu, Zexian Liu, Huai‐Qiang Ju, Chao Ren, Zhizhong Pan, Feng‐Hua Wang, Rui‐Hua Xu · Journal of Cancer · 2018
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2018
Abstract
Background: Programmed death ligand 1 (PD-L1) expression has been shown to predict benefit from anti-PD-1 treatment in several cancers.However, its predictive value in colorectal cancer seems limited.This study was aimed to explore the clinical and biomarker association of programmed death ligand 1 and its spatial heterogeneous expression in colorectal cancer.Methods: Tissue microarrays of 422 primary colorectal cancers from our hospital were used for the interpretation of PD-L1 and programmed death 1 (PD-1) expression, cluster of differentiation 4 (CD4) and CD8 density and microsatellite instability (MSI) status by immunohistochemistry.To assess the spatial heterogeneity of PD-L1 expression, Tissue microarrays of 383 paired intra-primary-tumor tissues, and 105 paired lymph node metastatic tumors and 64 paired distant metastatic tumors were also used.Results: PD-L1 was positive in 188 (44.5%) primary colorectal cancers.PD-L1 expression was associated with less advanced N category (P<0.001),less advanced TNM stage (P<0.001) and less nervous invasion (P=0.04).Higher PD-L1 expression was associated with higher PD-1 expression (P<0.001),higher CD4 (P<0.001) and CD8 (P<0.001) density and DNA mismatch repair deficiency (P=0.01).PD-L1 expression was associated with better disease-free survival and overall survival, but it was only an independent prognostic factor for disease-free survival (hazard ratio and 95% confidence interval: 0.42 [0.25-0.72],P<0.001).The probability of inconsistent PD-L1 expression was respectively 17.8%, 31.4% and 39.1% within primary tumors, between primary tumors and lymph node metastatic tumors, and between primary tumors and distant metastatic tumors.All the three differences were statistically significant (P<0.001,P<0.001 and P=0.05, respectively).Conclusions: PD-L1 expression was a marker of pre-existing immune responses in colorectal cancer, however, it was heterogeneously expressed in colorectal cancer, especially between primary and metastatic tumors.This might partially explain the low-efficiency of its predictive value for benefit from anti-PD-1 treatment.
Open the resolved locator · 10.7150/jca.27735
Metadata licence: OpenAlex metadata (CC0)